Global Health Concerns Create Business Opportunities - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Global Health Concerns Create Business Opportunities
Health crises generate support for new vaccines and treatments for diseases found in developing nations.

Pharmaceutical Technology
Volume 33, Issue 9, pp. 26-32

Treatments for tuberculosis

In Washington this month
The US Food and Drug Administration plays an important role in facilitating the development of new vaccines and drugs to protect against global infectious diseases. Its role may expand under Commissioner Margaret Hamburg, who built a strong record in public health and TB-control efforts as head of New York City's public-health department in the 1990s. That experience will help FDA encourage research on new TB treatments and counter a resurgence in multidrug-resistant and extensively drug-resistant TB strains.

The good news is that new TB-drug development and international collaborations are taking place. The trend demands clearer FDA guidelines on TB-drug testing. Current therapies are decades old, involve lengthy treatment courses, result in poor compliance, and generate resistant TB strains.

An FDA advisory-committee meeting in June supported establishing a research pathway with early endpoints for drugs to treat multidrug-resistant TB. The panel agreed that reduced bacterial count in sputum culture, followed by confirmatory trials to document low relapse rates, could accelerate the research and development (R&D) process, an approach that could be useful for the new compound being developed by Johnson & Johnson's (New Brunswick, NJ) Tibotec subsidiary with support from the Global Alliance for TB Drug Development (TB Alliance).

FDA followed up with a two-day workshop in July that delved into clinical-trial design challenges for drug-susceptible TB. The panel evaluated noninferiority study designs, combination-therapy regimens, problems of missing data, and early study endpoints. TB Alliance President Melvin Spigelman emphasized the importance of testing new combination-drug regimens that combat resistance and lead to individualized therapy. Gail Cassell, vice-president of Eli Lilly (Indianapolis), advocated "boldness in clinical-trial design," along with better postapproval adverse-event monitoring.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here